Hydrochlorothiazide is a thiazide diuretic indicated for hypertension and edema. We supply it to US manufacturers of tablets, capsules and fixed-dose combinations.
Data from PubChem (CID 3639) and FDA’s substance registry
CAS number
58-93-5
Molecular formula
C7H8ClN3O4S2
Molecular weight
297.7g/mol
FDA UNII
IUPAC name
6-chloro-1,1-dioxo-3,4-dihydro-2H-1lambda6,2,4-benzothiadiazine-7-sulfonamide
InChIKey
JZUFKLXOESDKRF-UHFFFAOYSA-N
- Appearance
- White or practically white crystalline powder.
- Solubility
- Slightly soluble in water, sparingly soluble in methanol, and freely soluble in sodium hydroxide solution and in dimethylformamide.
Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.
Worth settling with your inquiry
Used far more in fixed-dose combinations than alone, so one source often has to satisfy several product files. Its secondary amine makes N-nitroso-hydrochlorothiazide a standard item in the nitrosamine assessment.
On the US market
- Reference product
- MicrozideNDA 020504
- Approved ANDAs
- 16 with a marketed product
- Approved forms and strengths
- Tablet 12.5 mg, 25 mg, 50 mg
- Capsule 12.5 mg
- Powder for oral suspension 10 mg/mL
- Oral solution 50 mg/5 mL
Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.
Grade
USP or Ph. Eur. where a monograph exists, or your own specification.
Quantities
From development quantities for formulation work to commercial supply.
Packaging
To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.
Regulatory filings
US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.
Documents available with a quote
- Specification and certificate of analysis
- Safety data sheet
- Method of analysis
- DMF letter of authorization, where a US DMF is filed
- GMP certificate and inspection history of the site
- Residual solvents and elemental impurities statements
- Nitrosamine risk assessment
- TSE/BSE statement
Need something else for your QA file? Email info@yogpharma.com